Combatting cancer: how innovation actors are changing the landscape

En ligne
Blue microscopic cell against a red background

Désolé. Actuellement, cette page n'existe pas en français.

Discover the role of patents on cancer innovation and join us for the launch of a new study and EPO tools supporting scientists, health tech startups, and the cancer research community.

Event details

Événement passé
10:00 - 11:30 h
Online event

Enregistrements d'événements (en anglais)


Thursday 1 February 2024
10.00 hrs Welcome remarks
Nellie Simon
Vice-President Corporate Services, European Patent Office
10.10 hrs Key insights: Gaining momentum in technologies against cancer
Ilja Rudyk
Senior Economist, European Patent Office
10.20 hrs Presentation of the new Espacenet Platform for combatting Cancer
European Patent Office
10.25 hrs Interview
Thomas Baumert
Head, Inserm Institute IVH and Founder, Alentis Therapeutics
10.40 hrs Key insights: A new innovation business model in cancer research?
Ilja Rudyk
Senior Economist, European Patent Office
10.40 hrs Key insights: A new innovation business model in cancer research?
Ilja Rudyk
Senior Economist, European Patent Office
10.45 hrs

Key insights: EIC support and strategic actions in cancer
Iordanis Arzimanoglou

European Innovation Council
10.50 hrs Presentation of the Deep Tech Finder, Oncology Filter
Jeremy Philpott
European Patent Office
10.55 hrs Interview
Madiha Derouazi
Chief Scientific Officer, AC Immune and European Inventor Award Winner 2022
11.05 hrs Key insights: Europe and beyond
Ilja Rudyk
European Patent Office
11.10 hrs Interview
Jan-Willem Van de Loo
European Commission
11.25 hrs Q&A session and closing



Moderator: Rob Chapman

Rob Chapman is an examiner at the EPO (EN/DE). He joined the EPO in 2008 and is a specialist in the area of immunotherapeutics (vaccines and antibodies). In addition to searching and examining patent applications, Rob provides training and seminars for the European Patent Academy. Rob obtained his doctorate of natural sciences from the Ludwig Maximilian University in Munich (Germany) and an MBA from the Open University (UK).

Ilja Rudyk

Ilja Rudyk serves as senior economist at the EPO. He provides expert economic insight into issues relating to innovation and technology commercialisation, and has co-authored several studies on the role of patents and technology in the European economy.

Thomas Baumert

Thomas F. Baumert, MD is professor of medicine, director of the Institute of Translational Medicine and Liver Disease, Inserm U1110, director of the Laboratory of Excellence HEPSYS at the University of Strasbourg and chief of gastroenterology at the Center for Digestive Disease and Hepatology, Strasbourg University Hospitals. Furthermore, he is the founder, advisor and permanent guest to the board of Alentis Therapeutics – a clinical stage biotech company developing novel therapeutics for fibrotic diseases and cancer. He received his Doctor of Medicine from the University of Heidelberg, Germany and hold positions at Ludwig Maximilian University of Munich, University of Freiburg, the Massachusetts General Hospital, Harvard Medical School and the US National Institutes of Health. His research focuses on discovery of therapeutic targets for treatment of fibrosis and cancer using liver disease as a model. He has received numerous awards, published more than 400 scientific articles and is inventor on more than 30 patents and patent applications.

Iordanis Arzimanoglou

Iordanis Arzimanoglou is the Programme Manager for Health and Biotechnology at the EIC, responsible for developing visions for technological and innovation breakthroughs. Iordanis previously worked as an EIC Coach & Senior advisor to genomic/genetic SMEs. He was the CEO of the Thessaloniki Innovation Zone managing company, and prior to that, CEO of the Aarhus Biotech Cluster Company (BMF) and an Adjunct Associate Professor at Aarhus University. Earlier in his career, he was the Assistant Professor of Molecular Genetics at Weill Medical College of Cornell University and prior to that, he was Chief of Cancer Genetics Research Program at Lennox Hill Hospital and a research scientist in the Division of Medical Genetics at Weill Medical College of Cornell University. Iordanis holds a PhD from the University of Athens, Greece in Molecular Genetics and Biochemistry, a Boston University Graduate Certificate in international business management.  

Madiha Derouazi

Dr. Madiha Derouazi, an accomplished immunologist, joined AC Immune in January 2024 from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines. She is the winner of the European Inventor Award 2022 in the category SMEs. Previously, she founded AMAL Therapeutics in 2012, an immuno-oncology company developing a new generation of therapeutic cancer vaccines and served as CEO and CSO of the company until 2022. Dr. Derouazi led AMAL’s acquisition by Boehringer Ingelheim for EUR 425 million in 2019. During her career, she has taken numerous biologicals and advanced therapy medicinal products from research through pre-clinical development and first-in-human clinical trials. She holds a PhD in Cellular Biotechnology from the Swiss Federal Institute of Technology (EPFL) in Lausanne, which was followed by postdoctoral work concentrating on tumour immunology and vaccine development.

Jan-Willem van de Loo

Dr Jan-Willem van de Loo, Cancer Theme Lead at the European Commission Directorate-General Research and Innovation since 2019, has been a Policy and Scientific Officer at the European Commission in charge of cancer research since 2003. From September 2019 –to July 2021, he led a team co-creating the Horizon Europe Mission on Cancer. Other policy initiatives include contributions to the Europe’s Beating Cancer Plan, public-public and public private research and innovation  partnerships. He graduated in biology at the University of Utrecht in 1991, following a year in the UW-Madison Medical School Graduate Program. He worked as a junior scientist on blood coagulation at Sanquin, Amsterdam and obtained his PhD in cell biology at the Centre for Human Genetics at the University of Leuven in 1999. He held three postdoctoral positions in cancer research, including a Marie-Curie postdoctoral fellowship at the European Institute of Oncology in Milan.

Informations complémentaires

The Observatory on Patents and Technology at the European Patent Office (EPO) is delighted to invite you to the online event “Combatting cancer: how innovation actors are changing the landscape”. In a world increasingly driven by technological momentum and the commitment of governments to combat global public health issues, it is essential to understand how the innovation landscape is evolving to fight cancer. The EPO has a mission to disseminate the technological know-how disclosed in patents, including those which protect new solutions in cancer treatment and diagnostics.

Based on a thorough analysis of technological trends spanning a 50-year period, the EPO will present the key trends in cancer-fighting innovation and explore questions such as: Is the traditional innovation ecosystem undergoing a shift? And how do universities, public research organisations and startups, as well as large corporations, contribute to the development of cancer-fighting technologies? As we navigate this complex terrain, leaders in their field will share their insights on international technology trends, new business models and European policymaking.

This session will offer in-depth analysis of patent data and an introduction to tools for pinpointing relevant technical information. To facilitate the identification of cutting-edge cancer-fighting technologies in global patent databases, a new Espacenet tool developed specifically for the scientific community, in close collaboration with several European National Patent Offices, will be introduced. Additionally, considering patents as a crucial asset for economic actors seeking investments, especially in the health sector, our Deep Tech Finder, updated with new filters, will enable the search for start-ups specialized in cancer-fighting technology in Europe.

Who should attend

Everyone involved or with an interest in the cancer research ecosystem; cancer research organisations in Europe and around the world; industry involved in cancer treatment and diagnosis; policymaking at national and European Union level; health sector startups; universities and public research organisations; national patent offices; and other industry stakeholders, including cancer patient associations and intellectual property specialists in the health sector.